Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (4) | Back to Search
COMBINATION OF NAB-PACLITAXEL WITH TRASTUZUMAB AS NEOADJUVANT CHEMOTHERAPY FOR HER2-POSITIVE BREAST CANCER PATIENTS: EXPERIENCE FROM A SINGLE CENTER
- In: Poster Session
- At: Düsseldorf (Germany) (2015)
- Type: Poster
- By: LI, Tingting (Guangdong General Hospital; Sun Yat-sen University, Department of Pharmacy, Guangzhou, China)
- Co-author(s): Tingting Li
- Abstract:
Anthracycline-based neoadjuvant regimens are widely used for human epidermal growth factor receptor 2 (Her2)-positive breast cancer, which can lead to cardiac toxicity. In order to minimize this side effect, researchers begin to explore the anthracycline-free regimens. Attention was paid to the taxane-based ones.
From July 2009 to June 2014,
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023